|
|
4001 Miranda Avenue
Palo Alto, CA 94304 USA
phone:650-812-8700
fax:650-424-0832
|
|
| Symbol |
AFFY |
| Exchange |
Nasdaq |
| Founded |
2001 |
| Employees |
|
|
|
| www.affymax.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Peptide-based drugs for kidney diseases and cancer. |
|
| Management |
| Arlene M. Morris, President and Chief Executive Officer; Paul B. Cleveland, Chief Financial Officer and Executive Vice President; Anne-Marie Duliege, M.D., M.S., Chief Medical Officer; Jeffrey H. Knapp, Chief Commercial Officer; Kay Slocum, Senior Vice President, Human Resources |
| |
|
|
|
|
|
|
|
| Keywords |
| hematide, hemoglobin, hronic renal failure, heart failure, inflammatory |
|
|
|
| Description |
|
Affymax is developing a rich pipeline of synthetic peptide-based drugs against clinically validated targets for the treatment of kidney diseases and cancer. |
|
| Products / Services |
The company's lead productHematide is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for anemia due to chronic kidney disease (CKD) and cancer. Hematide is in late-stage clinical development with three Phase 2 clinical trials in patients with anemia due to chronic kidney disease currently enrolled in the U.S. and Europe.
|
|
| Technology / Differentiation |
| Affymax has amassed significant expertise in peptide drug discovery and development, including capabilities in creating long acting versions of drugs using PEGylation technology. While the company?s current efforts are focused on the development of Hematide, its core research and peptide libraries are available for future pipeline and/or licensing collaborations. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
